Andrew Smith, MD, PhD, chair of diagnostic imaging at St. Jude’s, joins the podcast to discuss the emerging field of radiomics and shares his hopes and skepticism. ...
The Uromigos
The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.
Latest Episode
Advertisement
Chuck Ryan, MD, joins the podcast to discuss various aspects of AR inhibition in prostate cancer.
Brian and Tom are joined by Dr. Chris Sweeney and Rob Jones to discuss the merits of various ARPIs in prostate cancer.
Returning guests Bertrand Tombal and Silke Gillessen join the podcast to dive into data from the 2024 APCCC.
Special guest Bertrand Tombal of Manchester Cancer Research Centre focuses on the historic and current data of AR inhibition
Christopher Cutie from J and J joins the show to discuss the SUNRISE bladder program.
Listen to the podcast format of the kidney cancer panel on IO after IO therapy from Uromigos Live 2024.
Advertisement
The Uromigos: Live and Unplugged 2023
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
Kidney Cancer Discussions
Listen to the podcast format of the kidney cancer panel on IO after IO therapy from Uromigos Live 2024.
Listen to the podcast format of the kidney cancer panel on TKI vs Ipi/Nivo vs IO/TKI from Uromigos Live 2024.
Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024.
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC.
Dr. Brian Rini’s Disclosures
Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis
Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai
Stock: PTC therapeutics
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.